Third-line therapies in patients with Kawasaki disease refractory to first- and second-line intravenous immunoglobulin therapy

被引：0
|
作者：
Takashi Furuta
Hiroki Yasudo
Seigo Okada
Yuji Ohnishi
Akiko Kawakami-Miyake
Yasuo Suzuki
Shouichi Ohga
Shunji Hasegawa
机构：
[1] Yamaguchi University Graduate School of Medicine,Department of Pediatrics
[2] Kyushu University,Department of Pediatrics, Graduate School of Medical Sciences
来源：
World Journal of Pediatrics | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：781 / 785
页数：4
相关论文
共 50 条
  • [31] Safety and efficacy of bortezomib and dexamethasone (BD) in multiple myeloma as first-line, second-line or third-line treatment
    Li, Juan
    Huang, Beihui
    Zhao, Ying
    Zheng, Dong
    Luo, Shaokai
    BLOOD, 2007, 110 (11) : 278B - 278B
  • [32] THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S93 - S94
  • [33] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [34] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Ozaslan, Ersin
    Topaloglu, Ulas Serkan
    Inanc, Mevlude
    Erdem, Umut Gokmen
    Demir, Hacer
    Arpaci, Erkan
    Seker, Mehmet Metin
    Karaaga, Mustafa
    Kiziltepe, Melih
    Eker, Baki
    Ozkan, Metin
    JOURNAL OF BUON, 2017, 22 (04): : 863 - 868
  • [35] Quadruple therapy: first- or second-line anti-Helicobacter pylori therapy?
    de Boer, WA
    TREATMENT OF GASTRO-OESOPHAGEAL REFLUX DISEASE AND HELICOBACTER PYLORI INFECTION, 1998, 20 (02): : 43 - 48
  • [36] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [37] First- and second-line therapy for advanced nonsmall cell lung cancer
    Sculier, J-P.
    Moro-Sibilot, D.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (04) : 915 - 930
  • [38] Docetaxel: Efficacy in first- and second-line therapy of advanced breast cancer
    Crown, J
    ONKOLOGIE, 2000, 23 : 1 - 3
  • [39] Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa
    Onoya, Dorina
    Nattey, Cornelius
    Budgell, Eric
    van den Berg, Liudmyla
    Maskew, Mhairi
    Evans, Denise
    Hirasen, Kamban
    Long, Lawrence C.
    Fox, Matthew P.
    AIDS PATIENT CARE AND STDS, 2017, 31 (05) : 205 - 212
  • [40] CLINICAL OUTCOMES OF SECOND-LINE TREATMENTS CYCLING IN REFRACTORY WET OVERACTIVE BLADDER PATIENTS BEFORE SWITCHING TO A THIRD-LINE THERAPY: A REAL WORLD OBSERVATIONAL STUDY
    Turco, Morena
    Gubbiotti, Marilena
    de Vermandois, Jacopo Adolfo Rossi
    Maglia, Daniele
    Mearini, Ettore
    Giannantoni, Antonella
    NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S10 - S11
12345